ICRA

Anil Matai, Director General, OPPI: "As India approaches the upcoming Union Budget, OPPI believes that there is an opportunity…

Industry experts weigh in on the latest tariff move. They highlight limited near-term disruption but caution about long-term risks…

According to ratings agency ICRA, revenues for Indian pharma companies are projected to expand by 7-9% in FY2026, supported by…

Budget provisions focus on customs duty exemptions, R&D funding, and healthcare infrastructure expansion

Focus on enabling MSME business, expanding PLI scheme and research-linked incentives to foster API innovation and tax incentives…

Revenues estimated to increase by 9-11 per cent from the US market, and 7-9 per cent each from the European and the domestic…

IIL partners with Central Institute of Brackishwater Aquaculture (CIBA), an Indian Council of Agricultural Research Institute for…

Revenue growth to moderate to 8-10 per cent in FY2025, post a healthy 13-14 per cent YoY expansion in FY2024

Revenues of ICRA’s sample set of companies to expand by 9-11 per cent in FY2024, OPM to improve by 150-200 bps to 22-23 per cent…